91 related articles for article (PubMed ID: 24902540)
1. Quercetin potentiates the antitumor activity of rituximab in diffuse large B-cell lymphoma by inhibiting STAT3 pathway.
Li X; Wang X; Zhang M; Li A; Sun Z; Yu Q
Cell Biochem Biophys; 2014 Nov; 70(2):1357-62. PubMed ID: 24902540
[TBL] [Abstract][Full Text] [Related]
2. Combination of YM155, a survivin suppressant with a STAT3 inhibitor: a new strategy to treat diffuse large B-cell lymphoma.
Kaneko N; Kita A; Yamanaka K; Mori M
Leuk Res; 2013 Sep; 37(9):1156-61. PubMed ID: 23746965
[TBL] [Abstract][Full Text] [Related]
3. Rituximab-induced HMGB1 release is associated with inhibition of STAT3 activity in human diffuse large B-cell lymphoma.
Zhao T; Ren H; Wang X; Liu P; Yan F; Jiang W; Li Y; Li J; Gribben JG; Jia L; Hao J
Oncotarget; 2015 Sep; 6(29):27816-31. PubMed ID: 26315113
[TBL] [Abstract][Full Text] [Related]
4. DCZ3301, a novel cytotoxic agent, inhibits proliferation in diffuse large B-cell lymphoma via the STAT3 pathway.
Sun X; Li B; Xie B; Xu Z; Chang G; Tao Y; Zhang Y; Chang S; Wang Y; Yu D; Xie Y; Li T; Wang H; Chen G; Hu L; Hou J; Zhang Y; Xiao W; Gao L; Shi J; Zhu W
Cell Death Dis; 2017 Oct; 8(10):e3111. PubMed ID: 29022919
[TBL] [Abstract][Full Text] [Related]
5. Combination of rituximab and mammalian target of rapamycin inhibitor everolimus (RAD001) in diffuse large B-cell lymphoma.
Xu ZZ; Wang WF; Fu WB; Wang AH; Liu ZY; Chen LY; Guo P; Li JM
Leuk Lymphoma; 2014 May; 55(5):1151-7. PubMed ID: 23841505
[TBL] [Abstract][Full Text] [Related]
6. Targeting the CD20 and CXCR4 pathways in non-hodgkin lymphoma with rituximab and high-affinity CXCR4 antagonist BKT140.
Beider K; Ribakovsky E; Abraham M; Wald H; Weiss L; Rosenberg E; Galun E; Avigdor A; Eizenberg O; Peled A; Nagler A
Clin Cancer Res; 2013 Jul; 19(13):3495-507. PubMed ID: 23637121
[TBL] [Abstract][Full Text] [Related]
7. Activation of the PI3K/AKT/mTOR pathway in diffuse large B cell lymphoma: clinical significance and inhibitory effect of rituximab.
Xu ZZ; Xia ZG; Wang AH; Wang WF; Liu ZY; Chen LY; Li JM
Ann Hematol; 2013 Oct; 92(10):1351-8. PubMed ID: 23636313
[TBL] [Abstract][Full Text] [Related]
8. Distinct apoptotic signaling characteristics of the anti-CD40 monoclonal antibody dacetuzumab and rituximab produce enhanced antitumor activity in non-Hodgkin lymphoma.
Lewis TS; McCormick RS; Emmerton K; Lau JT; Yu SF; McEarchern JA; Grewal IS; Law CL
Clin Cancer Res; 2011 Jul; 17(14):4672-81. PubMed ID: 21610152
[TBL] [Abstract][Full Text] [Related]
9. Rituximab regulates signaling pathways and alters gene expression associated with cell death and survival in diffuse large B-cell lymphoma.
Koivula S; Valo E; Raunio A; Hautaniemi S; Leppä S
Oncol Rep; 2011 Apr; 25(4):1183-90. PubMed ID: 21318224
[TBL] [Abstract][Full Text] [Related]
10. Quercetin exerts anti-melanoma activities and inhibits STAT3 signaling.
Cao HH; Tse AK; Kwan HY; Yu H; Cheng CY; Su T; Fong WF; Yu ZL
Biochem Pharmacol; 2014 Feb; 87(3):424-34. PubMed ID: 24275163
[TBL] [Abstract][Full Text] [Related]
11. The rGel/BLyS fusion toxin inhibits STAT3 signaling via down-regulation of interleukin-6 receptor in diffuse large B-cell lymphoma.
Lyu MA; Sung B; Cheung LH; Marks JW; Aggarwal BB; Aguiar RC; Rosenblum MG
Biochem Pharmacol; 2010 Nov; 80(9):1335-42. PubMed ID: 20654581
[TBL] [Abstract][Full Text] [Related]
12. MLN0905, a small-molecule plk1 inhibitor, induces antitumor responses in human models of diffuse large B-cell lymphoma.
Shi JQ; Lasky K; Shinde V; Stringer B; Qian MG; Liao D; Liu R; Driscoll D; Nestor MT; Amidon BS; Rao Y; Duffey MO; Manfredi MG; Vos TJ; D' Amore N; Hyer ML
Mol Cancer Ther; 2012 Sep; 11(9):2045-53. PubMed ID: 22609854
[TBL] [Abstract][Full Text] [Related]
13. Emerging immunotherapy and strategies directly targeting B cells for the treatment of diffuse large B-cell lymphoma.
Witkowska M; Smolewski P
Immunotherapy; 2015; 7(1):37-46. PubMed ID: 25572478
[TBL] [Abstract][Full Text] [Related]
14. Novel HDAC inhibitor Chidamide synergizes with Rituximab to inhibit diffuse large B-cell lymphoma tumour growth by upregulating CD20.
Guan XW; Wang HQ; Ban WW; Chang Z; Chen HZ; Jia L; Liu FT
Cell Death Dis; 2020 Jan; 11(1):20. PubMed ID: 31907371
[TBL] [Abstract][Full Text] [Related]
15. Quercetin abrogates IL-6/STAT3 signaling and inhibits glioblastoma cell line growth and migration.
Michaud-Levesque J; Bousquet-Gagnon N; Béliveau R
Exp Cell Res; 2012 May; 318(8):925-35. PubMed ID: 22394507
[TBL] [Abstract][Full Text] [Related]
16. At diagnosis, diffuse large B-cell lymphoma patients show impaired rituximab-mediated NK-cell cytotoxicity.
Danielou-Lazareth A; Henry G; Geromin D; Khaznadar Z; Briere J; Tamouza R; Cayuela JM; Thieblemont C; Toubert A; Dulphy N
Eur J Immunol; 2013 May; 43(5):1383-8. PubMed ID: 23400905
[TBL] [Abstract][Full Text] [Related]
17. A novel silicone derivative of natural osalmid (DCZ0858) induces apoptosis and cell cycle arrest in diffuse large B-cell lymphoma via the JAK2/STAT3 pathway.
Lu K; Li B; Zhang H; Xu Z; Song D; Gao L; Sun H; Li L; Wang Y; Feng Q; Chen G; Hu L; Wei R; Xie Y; Yu D; Wu X; Zhu W; Shi J
Signal Transduct Target Ther; 2020 Apr; 5(1):31. PubMed ID: 32296013
[TBL] [Abstract][Full Text] [Related]
18. Novel synthetic 4-chlorobenzoyl berbamine inhibits c-Myc expression and induces apoptosis of diffuse large B cell lymphoma cells.
Zhang L; Tong J; He X; Liang Y; Zhu L; Xu R; Zhao X
Ann Hematol; 2018 Dec; 97(12):2353-2362. PubMed ID: 30099568
[TBL] [Abstract][Full Text] [Related]
19. The novel triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid (CDDO) induces apoptosis of human diffuse large B-cell lymphoma cells through a peroxisome proliferator-activated receptor gamma-independent pathway.
Ray DM; Morse KM; Hilchey SP; Garcia TM; Felgar RE; Maggirwar SB; Phipps RP; Bernstein SH
Exp Hematol; 2006 Sep; 34(9):1202-11. PubMed ID: 16939813
[TBL] [Abstract][Full Text] [Related]
20. Arctigenin in combination with quercetin synergistically enhances the antiproliferative effect in prostate cancer cells.
Wang P; Phan T; Gordon D; Chung S; Henning SM; Vadgama JV
Mol Nutr Food Res; 2015 Feb; 59(2):250-61. PubMed ID: 25380086
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
